Kiniksa Pharmaceuticals International, plc Current Federal Tax Expense (Benefit)
Kiniksa Pharmaceuticals International, plc (KNSA) reported Current Federal Tax Expense (Benefit) of $16.67 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentFederalTaxExpenseBenefit · last filed 2026-02-24
- Kiniksa Pharmaceuticals International, plc current federal tax expense (benefit) for fiscal 2025 was $16.67M.
- Kiniksa Pharmaceuticals International, plc current federal tax expense (benefit) for fiscal 2024 was -$1.86M, a 1626.23% decline from fiscal 2023.
- Kiniksa Pharmaceuticals International, plc current federal tax expense (benefit) for fiscal 2023 was $122.00K, a 90.74% decline from fiscal 2022.
- Kiniksa Pharmaceuticals International, plc current federal tax expense (benefit) for fiscal 2022 was $1.32M.
| Period end | Current Federal Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $16.67M 10-K · filed 2026-02-24 |
| 2024-12-31 | -$1.86M 10-K · filed 2026-02-24 |
| 2023-12-31 | $122.00K 10-K · filed 2026-02-24 |
| 2022-12-31 | $1.32M 10-K · filed 2025-02-25 |